Joanna Kufel-Grabowska, K. Łukaszuk, Magdalena Błażek, A. Jagiełło-Gruszfeld, A. Horbaczewska, N. Irga-Jaworska, R. Jach, P. Jędrzejczak, I. Kopeć, M. Krawczuk-Rybak, Maciej Krzakowski, K. Pogoda, M. Sąsiadek, R. Spaczyński, M. Urbaniak, E. Wojciechowska-Lampka, S. Wołczyński, J. Jassem
{"title":"Fertility preservation during oncological treatment","authors":"Joanna Kufel-Grabowska, K. Łukaszuk, Magdalena Błażek, A. Jagiełło-Gruszfeld, A. Horbaczewska, N. Irga-Jaworska, R. Jach, P. Jędrzejczak, I. Kopeć, M. Krawczuk-Rybak, Maciej Krzakowski, K. Pogoda, M. Sąsiadek, R. Spaczyński, M. Urbaniak, E. Wojciechowska-Lampka, S. Wołczyński, J. Jassem","doi":"10.5603/ocp.2023.0033","DOIUrl":"https://doi.org/10.5603/ocp.2023.0033","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"24 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78221891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Takashi Kobayashi, S. Kanda, K. Tateishi, N. Morozumi, Ryouhei Yamamoto, F. Yoshiike, Hideaki Takizawa, Munetaka Takada, Manabu Yamamoto, K. Nishie, Takasuna Keiichiro, Toshihiko Agatsuma, M. Hama, Hozumi Tanaka, Akemi Matsuo, A. Morikawa, M. Hanaoka, T. Koizumi
{"title":"EGFR mutation and ALK fusion-positive non-small cell lung cancer: a multicenter prospective cohort study in Nagano Prefecture, Japan","authors":"Takashi Kobayashi, S. Kanda, K. Tateishi, N. Morozumi, Ryouhei Yamamoto, F. Yoshiike, Hideaki Takizawa, Munetaka Takada, Manabu Yamamoto, K. Nishie, Takasuna Keiichiro, Toshihiko Agatsuma, M. Hama, Hozumi Tanaka, Akemi Matsuo, A. Morikawa, M. Hanaoka, T. Koizumi","doi":"10.5603/ocp.2023.0038","DOIUrl":"https://doi.org/10.5603/ocp.2023.0038","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"27 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78159798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Radecka, J. Hudała-Klecha, Dariusz Sawka, Jolanta Sarga, Bożena Noworolska, Grażyna Susczyk, J. Sawicka, Elżbieta Duda, Natalia Obruśnik, Patryk Zając
{"title":"Home-based treatment with subcutaneous trastuzumab: safe and acceptable not only during a pandemic — final analysis of the RWD project ‘FlexCare’","authors":"B. Radecka, J. Hudała-Klecha, Dariusz Sawka, Jolanta Sarga, Bożena Noworolska, Grażyna Susczyk, J. Sawicka, Elżbieta Duda, Natalia Obruśnik, Patryk Zając","doi":"10.5603/ocp.2023.0025","DOIUrl":"https://doi.org/10.5603/ocp.2023.0025","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"38 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74069836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sezai Tunç, Z. Urakçı, S. Ebinç, S. Ileri, Z. Kalkan, Z. Oruç, M. Küçüköner, M. Kaplan, A. Işıkdoğan
{"title":"Survival outcomes of patients diagnosed with muscle-invasive bladder cancer who showed a response after neoadjuvant chemotherapy and refused radical cystectomy, and patients who had radical cystectomy or received chemoradiotherapy","authors":"Sezai Tunç, Z. Urakçı, S. Ebinç, S. Ileri, Z. Kalkan, Z. Oruç, M. Küçüköner, M. Kaplan, A. Işıkdoğan","doi":"10.5603/ocp.2023.0030","DOIUrl":"https://doi.org/10.5603/ocp.2023.0030","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"8 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88680246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Barbara Kopczyńska, Natalia Wierzejska, Paweł Sobczuk, P. Rutkowski
{"title":"Avapritinib in the treatment of gastrointestinal stromal tumors (GIST)","authors":"Barbara Kopczyńska, Natalia Wierzejska, Paweł Sobczuk, P. Rutkowski","doi":"10.5603/ocp.2023.0036","DOIUrl":"https://doi.org/10.5603/ocp.2023.0036","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"7 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88450493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Irene Solana López, Juan Antonio Guerra Martínez, D. Malón Giménez, L. Rodríguez Lajusticia, Carmen Pantín González, Ana Manuela Martín Fernández de Soignie, C. De Zea Luque, Beatriz Losada Vila, Nadia Sánchez Baños, Fátima Escalona Martín, Elia Martínez Moreno, D. Gutiérrez Abad, I. Juez Martel, B. Jiménez Munarríz, J. Calzas Rodríguez
{"title":"News and updates in the treatment of localized stage triple-negative breast cancer","authors":"Irene Solana López, Juan Antonio Guerra Martínez, D. Malón Giménez, L. Rodríguez Lajusticia, Carmen Pantín González, Ana Manuela Martín Fernández de Soignie, C. De Zea Luque, Beatriz Losada Vila, Nadia Sánchez Baños, Fátima Escalona Martín, Elia Martínez Moreno, D. Gutiérrez Abad, I. Juez Martel, B. Jiménez Munarríz, J. Calzas Rodríguez","doi":"10.5603/ocp.2023.0026","DOIUrl":"https://doi.org/10.5603/ocp.2023.0026","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"21 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89739372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adam Fałkowski, Aleksandra Żołnierek, J. Zolnierek
{"title":"Spectacular clinical benefit achieved by multidisciplinary management of a kidney cancer patient","authors":"Adam Fałkowski, Aleksandra Żołnierek, J. Zolnierek","doi":"10.5603/ocp.2023.0037","DOIUrl":"https://doi.org/10.5603/ocp.2023.0037","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"5 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85152870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Barbara Radecka, M. Gełej, Monika Kotyla, Tomasz Kubiatowski
Progress in understanding complex interactions between cancer cells and the immune system has led to the development of new methods of treatment — immunotherapy, modulating the anti-cancer response of the immune system. For several years, colorectal cancer (CRC) was thought to be a cancer with low immune stimulation potential, but in recent years the favorable prognostic value of lymphocytic infiltrates in the tumor has been noted. Currently it is well known that the stimulation of the immune system by CRC cells is associated with the accumulation of mutations in DNA microsatellites. This phenomenon results from impairment of function of genes (mainly MLH1, MSH2, MSH6 and PMS2) encoding proteins involved in correction of mismatched nucleotides during replication (dMMR), whose phenotypic reflection is microsatellite instability (MSI). It affects about 15–20% of CRC, with clear differences depending on the stage of cancer — about 20% in stage II, 12% in stage III, and only around 4% in stage IV. dMMR/MSI cancers are highly immunogenic through overexpression of tumor antigens and can induce a deep immune response. Cancers with intact repair gene system (pMMR) and stable microsatellites (MSS) show poor immunogenicity, which makes it difficult to induce an anti-tumor immune response. The relationship between impairment of the mismatch repair system and the induction of an anti-cancer immune response justifies the use of checkpoint inhibitors of this response in the treatment of patients with CRC MSI/dMMR. In MSS/pMMR cancers, checkpoint inhibitors used in monotherapy are not effective. However, studies are underway to combine these drugs with other methods of systemic treatment (chemotherapy, EGFR inhibitors, angiogenesis inhibitors, MET inhibitors), as well as radiotherapy.
{"title":"Immunotherapy for colorectal cancer","authors":"Barbara Radecka, M. Gełej, Monika Kotyla, Tomasz Kubiatowski","doi":"10.5603/ocp.2023.0027","DOIUrl":"https://doi.org/10.5603/ocp.2023.0027","url":null,"abstract":"Progress in understanding complex interactions between cancer cells and the immune system has led to the development of new methods of treatment — immunotherapy, modulating the anti-cancer response of the immune system. For several years, colorectal cancer (CRC) was thought to be a cancer with low immune stimulation potential, but in recent years the favorable prognostic value of lymphocytic infiltrates in the tumor has been noted. Currently it is well known that the stimulation of the immune system by CRC cells is associated with the accumulation of mutations in DNA microsatellites. This phenomenon results from impairment of function of genes (mainly MLH1, MSH2, MSH6 and PMS2) encoding proteins involved in correction of mismatched nucleotides during replication (dMMR), whose phenotypic reflection is microsatellite instability (MSI). It affects about 15–20% of CRC, with clear differences depending on the stage of cancer — about 20% in stage II, 12% in stage III, and only around 4% in stage IV. dMMR/MSI cancers are highly immunogenic through overexpression of tumor antigens and can induce a deep immune response. Cancers with intact repair gene system (pMMR) and stable microsatellites (MSS) show poor immunogenicity, which makes it difficult to induce an anti-tumor immune response. The relationship between impairment of the mismatch repair system and the induction of an anti-cancer immune response justifies the use of checkpoint inhibitors of this response in the treatment of patients with CRC MSI/dMMR. In MSS/pMMR cancers, checkpoint inhibitors used in monotherapy are not effective. However, studies are underway to combine these drugs with other methods of systemic treatment (chemotherapy, EGFR inhibitors, angiogenesis inhibitors, MET inhibitors), as well as radiotherapy.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"23 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75507042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Gełej, B. Radecka, Monika Kotyla, Weronika Radecka, T. Kubiatowski
{"title":"Immunotherapy for gastroesophageal cancer","authors":"M. Gełej, B. Radecka, Monika Kotyla, Weronika Radecka, T. Kubiatowski","doi":"10.5603/ocp.2023.0028","DOIUrl":"https://doi.org/10.5603/ocp.2023.0028","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"70 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86927284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this article, we discuss benign and malignant spermatic cord tumors. We attempted to compile this rare group of diseases by reviewing the international literature. Tumors of the spermatic cord are found very rarely. However, it is important to be aware of their occurrence, as they can cause a protrusion in the inguinal area. They are usually misdiagnosed as an inguinal hernia. The most common tumors in this area are benign — usually they are lipomas. In 20–70% of cases, adipose tumors accompany an inguinal hernia. Therefore, they should be kept in mind whenever a patient presents with symptoms of herniation in the inguinal region. Tumors of the spermatic cord may also involve the scrotum and manifest themselves as testicular hydrocele. Such a tumor is, for example, aggressive angiomyxoma. It is a locally malignant tumor that tends to infiltrate and compress the surrounding tissues but does not tend to give metastasis, therefore according to the WHO classification it is a benign tumor. However, malignant tumors such as rhabdomyosarcoma, which is the most common malignant neoplasm of testicular appendages, can also be located in the spermatic cord. The second most common soft tissue sarcoma is leiomyosarcoma, with poor initial prognosis, or metastases of malignant tumors from other organs, e.g. renal adenocarcinoma. As the prognosis for malignant tumors of the spermatic cord is generally dependent on the stage at the time of diagnosis, oncological vigilance and early diagnosis allow for faster detection of these tumors, which may improve the prognosis of patients with tumors in this location.
{"title":"Spermatic cord tumors — review of the literature","authors":"Krzysztof Kowalik, A. Modrzejewski, Adam Kurpik","doi":"10.5603/ocp.2023.0015","DOIUrl":"https://doi.org/10.5603/ocp.2023.0015","url":null,"abstract":"In this article, we discuss benign and malignant spermatic cord tumors. We attempted to compile this rare group of diseases by reviewing the international literature. Tumors of the spermatic cord are found very rarely. However, it is important to be aware of their occurrence, as they can cause a protrusion in the inguinal area. They are usually misdiagnosed as an inguinal hernia. The most common tumors in this area are benign — usually they are lipomas. In 20–70% of cases, adipose tumors accompany an inguinal hernia. Therefore, they should be kept in mind whenever a patient presents with symptoms of herniation in the inguinal region. Tumors of the spermatic cord may also involve the scrotum and manifest themselves as testicular hydrocele. Such a tumor is, for example, aggressive angiomyxoma. It is a locally malignant tumor that tends to infiltrate and compress the surrounding tissues but does not tend to give metastasis, therefore according to the WHO classification it is a benign tumor. However, malignant tumors such as rhabdomyosarcoma, which is the most common malignant neoplasm of testicular appendages, can also be located in the spermatic cord. The second most common soft tissue sarcoma is leiomyosarcoma, with poor initial prognosis, or metastases of malignant tumors from other organs, e.g. renal adenocarcinoma. As the prognosis for malignant tumors of the spermatic cord is generally dependent on the stage at the time of diagnosis, oncological vigilance and early diagnosis allow for faster detection of these tumors, which may improve the prognosis of patients with tumors in this location.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"71 3","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72454304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：